Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Simon Lord"'
Autor:
Simon Lord-Dufour, Susan E. Quaggin, Yves Duroche, Michael Ryczko, Aftab Taiyab, Heather Sheardown, Jing Jin, Pan Liu, Emily Anne Hicks, Jason Baardsnes, Xinfang Xie
Publikováno v:
Biotechnology and Bioengineering. 118:423-432
Vascular leak is a key driver of organ injury in diseases, and strategies that reduce enhanced permeability and vascular inflammation are promising therapeutic targets. Activation of the angiopoietin-1 (ANG1)-Tie2 tyrosine kinase signaling pathway is
Autor:
Sarah P. Blagden, Francesca M. Buffa, Isaac Kitchen-Smith, Natasha Sahgal, Matteo Di Giovannantonio, Adrian L. Harris, Gareth L. Bond, Simon Lord, Giovanni Stracquadanio, Lingyun Xiong, David A. Harris, Marsha D. Wallace, Benjamin Howell Lole Harris, Ping Zhang
Publikováno v:
Journal of Medical Genetics
Di Giovannantonio, M, Harris, B H, Zhang, P, Kitchen-Smith, I, Xiong, L, Sahgal, N, Stracquadanio, G, Wallace, M, Blagden, S, Lord, S, Harris, D, Harris, A H L, Buffa, F M & Bond, G L 2020, ' Heritable genetic variants in key cancer genes link cancer risk with anthropometric traits ', Journal of Medical Genetics . https://doi.org/10.1136/jmedgenet-2019-106799
Di Giovannantonio, M, Harris, B H, Zhang, P, Kitchen-Smith, I, Xiong, L, Sahgal, N, Stracquadanio, G, Wallace, M, Blagden, S, Lord, S, Harris, D, Harris, A H L, Buffa, F M & Bond, G L 2020, ' Heritable genetic variants in key cancer genes link cancer risk with anthropometric traits ', Journal of Medical Genetics . https://doi.org/10.1136/jmedgenet-2019-106799
BackgroundHeight and other anthropometric measures are consistently found to associate with differential cancer risk. However, both genetic and mechanistic insights into these epidemiological associations are notably lacking. Conversely, inherited ge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcb984c6d2a9691912d426cf78cb43cf
https://hdl.handle.net/11565/4052495
https://hdl.handle.net/11565/4052495
Autor:
Analia Azaro, Jordi Rodon, Constanza Linossi, Richard D. Baird, Ulrike Fiedler, Simon Lord, Keith M. Dawson, Aurelius Omlin, Nicolas Leupin, Andreas Harstrick, Stefanie Fischer, Michael T. Stumpp, Christof Zitt, Mark R. Middleton, Adrian L. Harris
Publikováno v:
Journal of Clinical Oncology
PURPOSE A first-in-human study was performed with MP0250, a DARPin drug candidate. MP0250 specifically inhibits both vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) with the aim of disrupting the tumor microenvironment. P
Autor:
Yves Durocher, Christian Gervais, Matthew Stuible, Sylvie Perret, Joseph D. Schrag, Simon Lord-Dufour, Gilles St-Laurent, Denis L'Abbé
Publikováno v:
Journal of Biotechnology
Highlights • CHO cells are more efficient than 293 cells for expressing trimeric SARS-CoV-2 spike protein. • A trimerization domain and elimination of the S1/S2 furin site are essential to obtain spike trimers. • Unprecedented trimeric spike ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08e8b78819ea45a1160bc87f03606905
https://doi.org/10.1101/2020.09.08.286732
https://doi.org/10.1101/2020.09.08.286732
Autor:
Mark R. Middleton, P S Virdee, Leena Elhussein, Martin Eatock, M Goff, Sharon Love, Anne Thomas, Stephen Falk, Joanna Moschandreas, Richard C. Turkington, D. Alan Anthoney, L Collins, Simon Lord
Publikováno v:
Thomas, A, Virdee, P S, Eatock, M, Lord, S R, Falk, S, Anthoney, D A, Turkington, R C, Goff, M, Elhussein, L, Collins, L, Love, S, Moschandreas, J & Middleton, M R 2020, ' Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma ', European Journal of Cancer, vol. 124, pp. 131-141 . https://doi.org/10.1016/j.ejca.2019.10.010
European Journal of Cancer
European Journal of Cancer
Background AZD8931 has equipotent activity against epidermal growth factor receptor, erbB2, and erbB3. Primary objectives were to determine the recommended phase II dose (RP2D) of AZD8931 + chemotherapy, and subsequently assess safety/preliminary cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3f3f4d7b04b1b1073ec0ebfa84b2946
https://pure.qub.ac.uk/en/publications/1ea96e9e-4701-4ab7-aa91-f416c1e2f897
https://pure.qub.ac.uk/en/publications/1ea96e9e-4701-4ab7-aa91-f416c1e2f897
Autor:
John Pollard, Penney, Sara M. Tolaney, H.-T. Arkenau, Geoffrey I. Shapiro, C. Murias, Simon Lord, Emma Dean, G. Conboy, Rui Tang, Carlos Becerra, Melinda L. Telli, Vandana G. Abramson, S.Z. Fields
Publikováno v:
Cancer Research. 78:OT2-07
Background: ATR is a critical regulator of the cellular response to replication stress; it signals DNA damage repair, mediated through homologous recombination. Many cancers depend on ATR to survive DNA damage. M6620 is a potent, selective inhibitor
Publikováno v:
Current Drug Targets. 17:1714-1727
Antiangiogenic resistance is a major problem in cancer therapeutics. Preclinical research has identified several compensatory proangiogenic pathways that arise upon vascular endothelial growth factor inhibition, several of which have led to the devel
Autor:
Simon Lord, Russell D. Petty, Daniel Swinson, Peter Hall, Michael I. Bennett, Galina Velikova, C. Handforth, Matthew T. Seymour, David A Cairns, Helen Marshall
Publikováno v:
Annals of Oncology. 30:v879-v880
Background Many pts with aGOAC are elderly and/or frail. GO2 [ASCO 2019 #4006] found that lower dose OxaliplatinCapecitabine (OCap) led to non-inferior progression free survival, less toxicity and better patient-centred outcomes using a novel composi
Autor:
Iain R. Macpherson, Ferry A.L.M. Eskens, Norbert P Koper, Elisabeth G.E. de Vries, Christian Rolfo, Cristina Saura, Sylvie Rottey, Udai Banerji, Jill J.J. Geenen, Marta Gil-Martin, Philippe Aftimos, Victor Moreno, E.C. Mommers, Simon Lord, Valentina Boni, Carla M.L. van Herpen, Fiona C Thistlethwaite
Publikováno v:
Lancet Oncology, 20(8), 1124-1135. ELSEVIER SCIENCE INC
The lancet oncology
Lancet Oncology, 20(8), 1124-1135. Lancet Publishing Group
Dipòsit Digital de la UB
Universidad de Barcelona
Lancet Oncology, 20, 1124-1135
Lancet Oncology, 20, 8, pp. 1124-1135
The lancet oncology
Lancet Oncology, 20(8), 1124-1135. Lancet Publishing Group
Dipòsit Digital de la UB
Universidad de Barcelona
Lancet Oncology, 20, 1124-1135
Lancet Oncology, 20, 8, pp. 1124-1135
Background Trastuzumab duocarmazine is a novel HER2-targeting antibody-drug conjugate comprised of trastuzumab covalently bound to a linker drug containing duocarmycin. Preclinical studies showed promising antitumour activity in various models. In th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b70692fb1a9fc695d8ac5957d5b08452
https://eprints.gla.ac.uk/185727/7/185727.pdf
https://eprints.gla.ac.uk/185727/7/185727.pdf
Autor:
Neel Patel, Lisa Ayers, Ioannis Roxanis, Luc Bidaut, Fredrik Karpe, Simon Lord, Mei Lin Ah-See, Christos E. Zois, Cameron Snell, Pankaj G. Roy, Christian Frezza, Leticia Campo, Adrian L. Harris, Francesca M. Buffa, Kevin M. Bradley, Ruth English, Fergus V. Gleeson, Tim James, R F Adams, Tom Metcalf, Syed Haider, Anand Sharma, Daniel R. McGowan, Dan Liu, Eugene J. Teoh, John D. Fenwick, Michael Pollak, Edoardo Gaude, Wei Chen Cheng, Simon Wigfield, Alastair M. Thompson
Publikováno v:
CELL METABOLISM
Cell Metabolism
Cell Metabolism
Late-phase clinical trials investigating metformin as a cancer therapy are underway. However, there remains controversy as to the mode of action of metformin in tumors at clinical doses. We conducted a clinical study integrating measurement of marker
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75a168f8387e5f05dbe5abffbe69c6fc
https://www.repository.cam.ac.uk/handle/1810/285637
https://www.repository.cam.ac.uk/handle/1810/285637